Related Experiment Video
Updated: Jun 10, 2026
Monitoring Functionality and Morphology of Vasculature Recruited by Factors Secreted by Fast-growing Tumor-generating Cells
Published on: November 23, 2014
Angiogenesis as a therapeutic target in urothelial carcinoma
Alvaro Pinto1, Andrés Redondo, Pilar Zamora
1Department of Medical Oncology, University Hospital La Paz, Madrid, Spain. alvaropintomarin@gmail.com
Abstract:
In the last few years, angiogenesis has confirmed its critical role in the development of malignant neoplasms. Antiangiogenic drugs, mainly bevacizumab, sorafenib, or sunitinib, are currently approved in a wide number of tumor types, such as breast, colorectal, liver, or kidney cancer, and have changed dramatically the evolution of our patients. Unfortunately, in urothelial carcinoma, which is a very common neoplasm, antiangiogenic agents are still in a very preliminary phase of clinical research. In this study, we focus on the biological basis of angiogenesis in urothelial tumors, its influence in the prognosis of these malignancies, and the available evidence about the use of antiangiogenic drugs in urothelial carcinoma.
Insights
Angiogenesis is vital in cancer development. While antiangiogenic drugs show promise in many cancers, their use in urothelial carcinoma is still under early clinical investigation.
Area of Science:
- Oncology
- Cancer Biology
- Medical Research
Background:
- Angiogenesis, the formation of new blood vessels, plays a crucial role in the growth and spread of malignant neoplasms.
- Approved antiangiogenic drugs like bevacizumab, sorafenib, and sunitinib have significantly impacted treatment outcomes for various cancers, including breast, colorectal, liver, and kidney cancer.
- Despite their success in other malignancies, antiangiogenic agents are in the early stages of clinical research for urothelial carcinoma.
Purpose of the Study:
- To explore the biological underpinnings of angiogenesis in urothelial tumors.
- To investigate the prognostic significance of angiogenesis in urothelial malignancies.
- To review the current evidence regarding the application of antiangiogenic drugs in urothelial carcinoma.
Main Methods:
- Literature review of studies on angiogenesis in urothelial carcinoma.
- Analysis of biological mechanisms driving angiogenesis in these tumors.
- Examination of clinical trial data and research on antiangiogenic therapies for urothelial cancer.
Main Results:
- Angiogenesis is confirmed as a critical factor in the development and progression of urothelial neoplasms.
- The study highlights the limited but emerging evidence for antiangiogenic therapies in this cancer type.
- Prognostic implications of angiogenesis in urothelial carcinoma are discussed based on available research.
Conclusions:
- Understanding angiogenesis is key to developing effective treatments for urothelial carcinoma.
- Further clinical research is essential to establish the role and efficacy of antiangiogenic drugs in urothelial cancer treatment.
- This review provides a foundation for future investigations into targeted antiangiogenic therapies for urothelial malignancies.
Related Concept Videos
01:10Mechanism of Angiogenesis
01:24Regulation of Angiogenesis and Blood Supply
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
01:27Tumor Immunotherapy